XML 64 R35.htm IDEA: XBRL DOCUMENT v3.21.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)
 1 Months Ended 3 Months Ended 12 Months Ended 40 Months Ended 47 Months Ended 87 Months Ended
Jul. 27, 2020
USD ($)
Apr. 05, 2018
USD ($)
Sep. 30, 2020
USD ($)
Aug. 31, 2020
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
Feb. 29, 2020
USD ($)
product_target
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Aug. 31, 2019
USD ($)
May 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jan. 31, 2014
USD ($)
program
Mar. 31, 2021
USD ($)
option
product_target
royaltyFee
product
Mar. 31, 2020
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
milestone
product
Mar. 31, 2021
USD ($)
milestone
Mar. 31, 2021
USD ($)
product
milestone
Feb. 28, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               $ 26,280,000 $ 13,076,000          
Other long-term liabilities                               7,228,000   $ 7,011,000 $ 7,228,000 $ 7,228,000 $ 7,228,000  
California institute for regenerative medicine agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Funds due under the agreement                       $ 8,000,000.0                    
Other long-term liabilities                               6,600,000   6,400,000 6,600,000 6,600,000 6,600,000  
California institute for regenerative medicine agreement | Research grants                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               5,200,000            
Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               6,200,000 0          
Novartis Institutes for BioMedical Research, Inc. | Research services                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               1,700,000 0          
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Proceeds from collaborators       $ 75,000,000.0                           75,000,000.0        
Collaborative arrangement transaction price $ 95,100,000                                          
License fee 75,000,000.0                                          
Collaborative arrangement estimated reimbursable service costs 20,100,000                                          
Deferred revenue                               64,700,000   70,900,000 64,700,000 64,700,000 64,700,000  
Financial advisory fees                                   $ 1,500,000        
Percent of initial recognition                                   2.00%        
Amortization                               100,000 0          
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received 420,000,000.0                                          
Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of commercial milestones | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received $ 300,000,000.0                                          
Biogen MA, Inc. | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               7,300,000 0          
Biogen MA, Inc. | Research services                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               $ 3,100,000 0          
Biogen MA, Inc. | Collaboration and license agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Proceeds from collaborators         $ 125,000,000.0     $ 125,000,000.0                            
Consideration received on transaction                                   $ 204,600,000        
Maximum milestone payment receivable               $ 2,370,000,000                            
Number of product targets | product_target               12                            
Number of product targets selected | product_target               3                            
Number of additional product targets | product_target               9                            
Target selection period               5 years                            
Maximum number of product targets replaced | product_target                               10            
Financial advisory fees                                   $ 7,000,000.0        
Percent of initial recognition                                   2.00%        
Portion of contract asset recognized                                   $ 4,100,000        
Amortization                               $ 100,000 0          
Biogen MA, Inc. | Collaboration and license agreement | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Research period               7 years                            
Biogen MA, Inc. | Collaboration and license agreement | Pre-approval milestone                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Maximum milestone payment receivable               $ 925,000,000.0                            
Biogen MA, Inc. | Collaboration and license agreement | Sales-based milestone                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Maximum milestone payment receivable               $ 1,450,000,000                            
Biogen MA, Inc. | Stock purchase agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Deferred revenue                               175,900,000   183,200,000 175,900,000 175,900,000 175,900,000  
Number of shares issued in transaction (in shares) | shares           24,420,157                                
Sale of stock, price per share (in dollars per share) | $ / shares           $ 9.2137                                
Consideration received on transaction           $ 225,000,000.0                       204,600,000        
Standstill restriction period               3 years                            
Standstill restriction, ownership threshold percentage ownership percentage                                           5.00%
Agreement restriction, percentage of shares held                                           50.00%
Voting provisions expiration period               2 years                            
Voting provisions, ownership threshold percentage                                           5.00%
Excess consideration received on transaction                                   79,600,000        
Collaboration agreement, equity issued                                   145,400,000        
Recognized portion of equity issued                                   2,900,000        
Kite Pharma, Inc.                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               6,288,000 7,219,000          
Kite Pharma, Inc. | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               6,159,000 6,227,000          
Kite Pharma, Inc. | Research services                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               129,000 992,000          
Kite Pharma, Inc. | Collaboration and license agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Collaborative arrangement transaction price                   $ 189,300,000                        
Collaborative arrangement estimated reimbursable service costs                   39,300,000                        
Deferred revenue                               $ 75,300,000   81,400,000 75,300,000 75,300,000 75,300,000  
Milestone payments received   $ 150,000,000.0                                        
Initial research term of agreement                               6 years            
Number of options to extend initial research term | option                               2            
Extended research term of agreement                               1 year            
Separate upfront fee                               $ 10,000,000.0            
Collaborative arrangement estimated reimbursable service costs for new research plan                   3,400,000                        
Revenues under agreement                   $ 150,000,000.0                        
Kite Pharma, Inc. | Collaboration and license agreement | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received   3,010,000,000.00                                        
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Contingent development - and sales-based milestone payments to be received   1,260,000,000                                        
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Contingent development - and sales-based milestone payments to be received   $ 1,750,000,000                                        
Pfizer Inc.                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone payments received                         $ 12,000,000.0                  
Revenues under agreement                 $ 25,000,000.0                          
Contract to perform for others, cumulative compensation earned                                   25,000,000.0        
Increase (decrease) in revenue             $ 2,400,000                              
Increase (decrease) in net loss             $ 2,400,000                              
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares             $ (0.02)                              
Pfizer Inc. | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                                 400,000          
Pfizer Inc. | SB-525 and other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues under agreement                           $ 70,000,000.0                
Pfizer Inc. | C9ORF72                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                                     $ 5,000,000.0      
Collaborative arrangement transaction price                         17,000,000.0                  
Milestone payments received                         12,000,000.0                  
Agreement termination, term                               15 years            
Revenues under agreement                         5,000,000.0         5,000,000.0        
Number of products approved | product                                     0      
Number of milestones included in transaction price | milestone                                     0      
Pfizer Inc. | Maximum | SB-525 and other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Potential amount to be funded for achievement of specified commercialized and sales milestones                           266,500,000                
Pfizer Inc. | Maximum | SB-525                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone revenue receivable                           300,000,000.0                
Pfizer Inc. | Maximum | Other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone revenue receivable                           175,000,000.0                
Pfizer Inc. | Phase 3 clinical trial                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received     $ 30,000,000.0                                      
Contract to perform for others, cumulative compensation earned                                   30,000,000.0        
Pfizer Inc. | Achievement of specified clinical development intellectual property and regulatory milestones | Maximum | SB-525 and other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                           208,500,000                
Pfizer Inc. | Achievement of first commercial sale milestones | Maximum | SB-525 and other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                           $ 475,000,000.0                
Pfizer Inc. | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum | C9ORF72                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                         60,000,000.0                  
Pfizer Inc. | Achievement of commercial milestones | Maximum | C9ORF72                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                         $ 90,000,000.0                  
Pfizer SB-525                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Collaborative arrangement transaction price                               $ 134,000,000.0            
Agreement termination, term                               15 years            
Revenues under agreement                               $ 55,000,000.0            
Research service fees                               $ 79,000,000.0            
Pfizer SB-525 | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                                 2,200,000          
Pfizer SB-525 | SB-525 and other products                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone payments received                                       $ 55,000,000.0    
Number of milestones achieved | milestone                                       2    
Number of products approved | product                               0            
Number of milestones included in transaction price | royaltyFee                               0            
Pfizer SB-525 | Milestone achievement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                                 1,000,000.0          
Sanofi                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               $ 1,060,000 499,000          
Agreement termination, term                               180 days            
Revenues under agreement                             $ 20,000,000.0              
Milestone revenue receivable                               $ 6,000,000.0     $ 6,000,000.0 $ 6,000,000.0 $ 6,000,000.0  
Number of products approved | product                                         0  
Number of research programs | program                             2              
Increase (decrease) in revenue                                 (2,200,000)          
Increase (decrease) in net loss                                 $ 2,200,000          
Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares                                 $ (0.02)          
Sanofi | Recognition of license and stand-ready fee                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               227,000 $ (729,000)          
Sanofi | Milestone achievement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               154,000 (492,000)          
Sanofi | Research services                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Revenues                               679,000 $ 1,720,000          
Sanofi | Collaboration and license agreement                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Collaborative arrangement transaction price                             $ 93,300,000              
Collaborative arrangement estimated reimbursable service costs                             59,800,000              
Deferred revenue                               800,000   $ 1,200,000 800,000 800,000 $ 800,000  
Revenues under agreement                             20,000,000.0              
Number of milestones included in transaction price | milestone                                         0  
Cumulative milestone achieved                               7,300,000     7,300,000 7,300,000 $ 7,300,000  
Sanofi | Collaboration and license agreement | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                             276,300,000              
Sanofi | Collaboration and license agreement | Milestone two                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone revenue receivable                 $ 7,500,000             7,500,000     7,500,000 7,500,000 7,500,000  
Milestone revenue reversal                               100,000     100,000 100,000 100,000  
Sanofi | Collaboration and license agreement | Milestone three                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone revenue receivable                               13,500,000     13,500,000 13,500,000 13,500,000  
Sanofi | Collaboration and license agreement | ST-40 Beta Thalassemia Phase 1 clinical trial milestone                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Milestone payments received                     $ 6,000,000.0                      
Milestone revenue reversal                               100,000     100,000 100,000 100,000  
Cumulative milestone achieved                               $ 5,900,000     $ 5,900,000 $ 5,900,000 $ 5,900,000  
Sanofi | Collaboration and license agreement | Achievement of specified clinical development And regulatory milestones | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                             115,800,000              
Sanofi | Collaboration and license agreement | Achievement of specified sales milestones | Maximum                                            
Research and Development Arrangement, Contract to Perform for Others [Line Items]                                            
Development and sales-based milestone payments to be received                             $ 160,500,000